http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 23 Apr 2025 19:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html <div class="xn-content"> <p><b>Strategic Expansion Paired with Over <money>$1M</money> in Annual Cost Savings from Operational Restructuring</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>April 23, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. <location value="LC/de" idsrc="xmltag.org" >Germany</location>, as the largest healthcare market in <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</p> <p>In parallel, the Company has successfully completed http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Enters+Germany+-+Europe%27s+Largest+Market/24677257.html Wed, 23 Apr 2025 19:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>March 16, 2025</chron></span> /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.</p> <p><b>Key Findings:</b></p> <ul type="disc"><li><b>No drug-related adverse events</b>, reinforcing CimetrA®'s safety.</li><li><b>Faster clinical improvement</b> versus placebo, measured by the WHO Ordinal Scale.</li><li><b>Reduced inflammation</b>, with significant modulation of key inflammatory http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Expands+Pipeline+with+Promising+Drug+CimetrA%C2%AE/24505193.html Sun, 16 Mar 2025 18:00:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html <div class="xn-content"> <p><b>Advanced wound care market projected to exceed <money>$15 billion</money> globally by 2030</b></p> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH</location>, Australia </span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span>Argent BioPharma Ltd.</span> </b>(ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.</p> <p><b>SINTEF, headquartered in Trondheim, <location value="LC/no" idsrc="xmltag.org" >Norway</location>, is an independent research organization founded in 1950 that conducts contract research and development projects.</b></p> <p><b>Key Developments:</b></p> <ul type="disc"><li><b>O</b>ptimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, http://www.streetinsider.com/PRNewswire/Argent+BioPharma+Ltd.+Updates+on+SINTEF+Collaboration+for+Chronic+Wound+Management/24338134.html Wed, 12 Feb 2025 17:30:00 -0400 MXC O.03969348 RGT RGTLF http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Raised+US%244%2C500%2C000/24177132.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..perth" idsrc="xmltag.org" >PERTH, Australia</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2025</chron></span> /PRNewswire/ -- Argent BioPharma (ASX:RGT) (OTCQB:RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology.</p> <p>The company announces the successful completion of a <money>US$4,500,000</money> (before costs) capital raise (<b>Placement</b>) through the subscription of 5,625,000 Units, each priced at <money>US$0.80</money> (<money>~A$1.28</money>). Each Unit comprises two (2) fully paid ordinary shares (<b>Placement Shares</b>) and one (1) free-attaching warrant, exercisable at <money>US$0.55</money> (<money>~A$0.88</money>) with an expiry date of three years from issuance (<b>Warrants</b>).</p> <p>The Placement will be conducted http://www.streetinsider.com/Press+Releases/Argent+BioPharma+Ltd.+Raised+US%244%2C500%2C000/24177132.html Tue, 07 Jan 2025 06:23:00 -0400 MXC O.03969348 RGT RGTLF RQHTF